Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib monotherapy in driver-negative NSCLC after failure of second-line chemotherapy
ChiCTR1800019537Phase 4Not yet recruiting
- Sponsor
- Fuling Central Hospital
- Start
- Nov 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Fuling Central Hospital. Primary endpoint: progression-free survival. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019537.